IceCure Medical’s ProSense cryoablation shows efficacy in kidney tumor study

IceCure Medical (ICCM) announced interim results from the company’s ICESECRET study of cryoablation for patients with small renal masses who cannot be offered kidney preserving surgery. Data were presented on December 5 at the Israeli Urological Association Conference in Eilat, Israel. In 91 patients, approximately 82%, no tumor recurrence was observed. Following an additional cryoablation procedure for the same tumor in 13 patients, the success rate for the overall population was 83.8%, with a mean follow-up time of 39.6 months. In patients without a history of kidney cancer with one tumor less than 3 cm, the success rate was 88.7%. Freezing of the renal tumor, including safety margins of 0.5 cm, was achieved in 95.6% of the procedures demonstrating high efficacy in cases without anatomic limitation for ice ball creation. Four procedure-related serious adverse events were reported, three of which were mild and treated conservatively. One severe complication was observed seven months after the cryoablation procedure. Procedure time was short at approximately 25 minutes.